Researches are advancing it mainly for use in mosquito surveillance efforts, but also collected data supporting clinical testing of human samples.
The studies provide further support for Meridian's Illumigene Malaria as a tool for routine screening of travelers in non-endemic areas of the world.
The device, which will be tested in collaboration with a Panamanian research institute, will run 40-minute tests without the need for electricity.
The company's net earnings rose, and it reaffirmed its guidance of $195 million to $200 million in revenues for full year 2016.
The LAMP-based test is faster and more sensitive, allowing faster treatment and more accurate diagnosis for malaria patients.
HiberGene will use the funding to develop and commercialize tests for Group B Streptococcus, Clostridium difficile, and norovirus.
The company plans to add assays for Group B Streptococcus, Clostridium difficile, and norovirus in 2016 to complement its existing meningitis test.
The instrument is designed exclusively for use with the company's portfolio of molecular infectious disease assays, including its recently launched HG Meningococcus
Meridian's Diagnostics segment grew 2 percent lifted by a 10 percent increase in revenues from the illumigene molecular product line.
The revenue increase was driven by growth in Meridian's Diagnostics segment and particularly sales of its Illumigene product line.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.
DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.
In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.
A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.